Germán E. Sánchez-Morales, Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”; Mexico City, Mexico
Jorge L. Osorio-Serrano, Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”; Mexico City, Mexico
Alan Guerrero-Gómez, Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”; Mexico City, Mexico
Carlos Chan, Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”; Mexico City, Mexico
Ismael Domínguez-Rosado, Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”; Mexico City, Mexico
Introduction: Pancreas is considered one of the organs most frequently affected by recurrence after nephrectomy secondary to renal cell carcinoma reporting an incidence of 20%, 85% of these occur within the first 3 years. Objective: The objective of the study is to evaluate overall survival and disease-free survival in patients with renal cancer and pancreatic metastases who underwent surgical treatment. Methods: A retrospective cross-sectional study of patients with histological diagnosis of renal cancer associated with pancreatic metastasis was performed and included those treated by pancreatoduodenectomy or distal pancreatectomy during the period 1987-2020. Results: 14 patients with pancreatic metastasis were included. Two groups of patients were obtained: those who underwent pancreatic surgery for metastasis and those who did not undergo surgical procedure. According to the location of the metastasis, 71.4% corresponded to a single location and 28.6% to multiple locations. 57.1% underwent Whipple and 42.9% distal pancreatectomy. Survival after the surgical procedure was 1150 days versus 499 days in non-operated patients. Conclusion: Pancreatic metastases due to RCC can be curable, improve morbidity, and increase disease-free survival with surgical treatment.
Keywords: Renal cancer. Metastasis. Whipple. Pancreas. Survival. Distal pancreatectomy.